PAO Group, Inc. announced the company has finalized plans to launch its CBD pet product line in December. Last year, the company acquired intellectual property derived through research into CBD extracted in association with a patented extraction method. PAOG is developing both pharmaceutical and nutraceutical treatments for humans based on this intellectual property. Today, for the first time, the company revealed it is also developing CBD products for pets. PAOG recently announced the launch of its first two CBD nutraceutical products, RelaxRX CBD, a sleep aid, and RehabRX CBD, a salve. PAOG is on track to realize its first revenue this year, starting in Fourth Quarter 2021, since acquiring the extraction technology. PAOG has confirmed shipping its first and second CBD nutraceutical product to its distribution partner, North American Cannabis Holdings, Inc. (OTC Pink: USMJ). The product will soon be for sale online. PAOG expects revenue to grow rapidly following its first and second CBD nutraceutical product launches as the company has follow-on products lined up to follow these products, adding to overall sales potential.